The SVP Legal & General Counsel of Ionis Pharmaceuticals Inc (IONS) is Selling Shares


Today, the SVP Legal & General Counsel of Ionis Pharmaceuticals Inc (IONS), Patrick O’neil, sold shares of IONS for $250.2K.

Following Patrick O’neil’s last IONS Sell transaction on September 07, 2017, the stock climbed by 28.6%. In addition to Patrick O’neil, one other IONS executive reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on Ionis Pharmaceuticals Inc’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $192 million and quarterly net profit of $320 million. In comparison, last year the company earned revenue of $144 million and had a GAAP net loss of $1.42 million. IONS’s market cap is $11.33B and the company has a P/E ratio of 45.98. Currently, Ionis Pharmaceuticals Inc has an average volume of 1.38M.

Based on 6 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $75.17, reflecting a -11.6% downside.

The insider sentiment on Ionis Pharmaceuticals Inc has been negative according to 60 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Patrick O’neil’s trades have generated a -21.9% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs.

Read More on IONS:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts